Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thromb Thrombolysis
Autores principales: Mantha, Simon, Laube, Eva, Miao, Yimei, Sarasohn, Debra M., Parameswaran, Rekha, Stefanik, Samantha, Brar, Gagandeep, Samedy, Patrick, Wills, Jonathan, Harnicar, Stephen, Soff, Gerald A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5318467/
https://ncbi.nlm.nih.gov/pubmed/27696084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-016-1429-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares